Patents by Inventor Leslie D. Bell

Leslie D. Bell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
    Patent number: 6130333
    Abstract: The present invention provides for compounds having the following Formulae I-III, ##STR1## and ##STR2## The compounds of the present invention are useful in the treatment of a variety of disease such as glaucoma, sexual dysfunction, asthma and cardiovascular disorders such as stable-, unstable- and variant-angina, hypertension, pulmonary hypertension, congestive heart failure, atherosclerosis, and thrombosis.
    Type: Grant
    Filed: November 27, 1998
    Date of Patent: October 10, 2000
    Assignee: Monsanto Company
    Inventors: Horng-Chih Huang, Timothy S. Chamberlain, Steven Lynn Settle, William Dean Joy, Ned R. Siegel, Leslie D. Bell
  • Modified tissue plasminogen activator with modified glycosylation site
    Patent number: 5244676
    Abstract: A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a fibronectin finger-like domain F, a growth factor domain GF, a sequence of two K2 kringle regions and a serine protease region SP, wherein the first of said kringles is free of any glycosylation site and the second of said kringles has a single glycosylation site.
    Type: Grant
    Filed: June 6, 1988
    Date of Patent: September 14, 1993
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates
    Patent number: 5114711
    Abstract: Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides have new and particularly useful activities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.
    Type: Grant
    Filed: July 13, 1989
    Date of Patent: May 19, 1992
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, Keith G. McCullagh, Alan G. Porter
  • Modified tissue plasminogen activator K2K2SP
    Patent number: 5100666
    Abstract: A modified t-PA having improved in vivo half-life is disclosed comprising in sequence a sequence of two K2 kringle regions and a serine protease region SP.
    Type: Grant
    Filed: June 6, 1988
    Date of Patent: March 31, 1992
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • Modified tissue plasminogen activator substituted at cysteine-73 and lysine-277
    Patent number: 5037752
    Abstract: A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg and at the site Lys277.fwdarw.Asp.
    Type: Grant
    Filed: April 3, 1989
    Date of Patent: August 6, 1991
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • Tissue plasminogen activator modified by the substitution of Arg for Cys at position 73, methods and pharmaceutical compositions therefor
    Patent number: 4963357
    Abstract: A modified tissue plasminogen activator having an improved in vivo half-life characterized in that the normal protein moiety of 527 amino acids is mutated at the site Cys73.fwdarw.Arg.
    Type: Grant
    Filed: January 29, 1988
    Date of Patent: October 16, 1990
    Assignee: Monsanto Company
    Inventors: Leslie D. Bell, Ernest J. Mayer, Mark O. Palmier, H. Eser Tolunay, Thomas G. Warren, Tze-Chein Wun
  • Covalently linked polypeptide cell modulators
    Patent number: 4935233
    Abstract: Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides have new and particularly useful activities when the component polypeptide cell modulators are interferons, lymphokines or cytotoxins which act through different and specific cell receptors to initiate complementary biological activities.
    Type: Grant
    Filed: December 2, 1985
    Date of Patent: June 19, 1990
    Assignee: G. D. Searle and Company
    Inventors: Leslie D. Bell, Keith G. McCullagh, Alan G. Porter
  • Structure and properties of modified interferons
    Patent number: 4914033
    Abstract: A composition of matter comprising a polypeptide of the formula:A-R.sub.1 -B-R.sub.2-22 -CwhereinA is the amino acid sequence 1-16 of human beta interferon;R.sub.1 is cysteine, serine or alanine;B is the amino acid sequence 18-31 of human beta interferon;R.sub.2-22 are naturally occurring amino acids;C is the amino acid sequence 53-166 of human beta interferon.
    Type: Grant
    Filed: May 18, 1988
    Date of Patent: April 3, 1990
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, Paul G. Boseley, Alan G. Porter
  • Modified (1-56) beta interferons
    Patent number: 4793995
    Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 56 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.
    Type: Grant
    Filed: June 22, 1984
    Date of Patent: December 27, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Paul G. Boseley
  • Structure and properties of modified interferons
    Patent number: 4769233
    Abstract: A composition of matter comprising a polypeptide of the formula:A-R.sub.1 -B-R.sub.2-22.sup.-Cwherein:A is the amino acid sequence 1-16 of human beta interferon;R.sub.1 is cysteine, serine or alanine;B is the amino acid sequence 18-31 of human beta interferon;R.sub.2-22 are naturally occurring amino acids;C is the amino acid sequence 53-166 of human beta interferon.
    Type: Grant
    Filed: May 3, 1985
    Date of Patent: September 6, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, Paul G. Boseley, Alan G. Porter
  • Modified (80-113) beta interferons
    Patent number: 4753795
    Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 80 to 113 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.
    Type: Grant
    Filed: June 22, 1984
    Date of Patent: June 28, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Paul G. Boseley, Michael Houghton
  • Interferons with novel cysteine pattern
    Patent number: 4751077
    Abstract: Human interferons containing novel cysteine substitutions and disulfide bonds are disclosed. The amino acid sequence of a first interferon is combined with the cysteine and/or disulfide pattern of a second interferon resulting in a molecule with hybrid properties.
    Type: Grant
    Filed: November 30, 1984
    Date of Patent: June 14, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Alan G. Porter, John R. Adair
  • Modified (1-28) beta interferons
    Patent number: 4738844
    Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 1 to 28 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.
    Type: Grant
    Filed: June 22, 1984
    Date of Patent: April 19, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Paul G. Boseley, Michael Houghton
  • Modified (115-145) beta interferons
    Patent number: 4738845
    Abstract: Modified beta interferons containing amino acid substitutions in the beta interferon amino acids 115 to 145 are described. These modified beta interferons exhibit changes in the antiviral, cell growth regulatory or immunomodulatory activities when compared with unmodified beta interferon.
    Type: Grant
    Filed: June 25, 1984
    Date of Patent: April 19, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Leslie D. Bell, John C. Smith, Paul G. Boseley, Michael Houghton
  • Synthetic urogastrone gene, corresponding plasmid recombinants, transformed cells, production thereof and urgastrone expression
    Patent number: 4719180
    Abstract: A synthetic gene characterised in that it codes for the expression of urogastrone or a sub-unit thereof is disclosed.The production thereof by the assembly and ligation of a number of nucleotide blocks is also disclosed, as are corresponding plasmid recombinants, transformed cells and the production thereof.The expression of urogastrone is further disclosed.Urogastrone is a polypeptide hormore (protein) which may be isolated in small amounts from human urine. It has an application in the treatment of ulcers and in the promotion of wound healing. The present invention provides a more viable commercial production.
    Type: Grant
    Filed: September 13, 1984
    Date of Patent: January 12, 1988
    Assignee: G. D. Searle & Co.
    Inventors: Michael A. W. Eaton, Michael T. Doel, Norman H. Carey, John C. Smith, David M. J. Lilley, Leslie D. Bell